CN101200460B - 二氢苯并吡喃酮类化合物及其用途 - Google Patents
二氢苯并吡喃酮类化合物及其用途 Download PDFInfo
- Publication number
- CN101200460B CN101200460B CN2007101776289A CN200710177628A CN101200460B CN 101200460 B CN101200460 B CN 101200460B CN 2007101776289 A CN2007101776289 A CN 2007101776289A CN 200710177628 A CN200710177628 A CN 200710177628A CN 101200460 B CN101200460 B CN 101200460B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- pharmacy acceptable
- acceptable salt
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 ketone compound Chemical class 0.000 title claims description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 35
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 31
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 8
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 8
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 8
- 208000019622 heart disease Diseases 0.000 claims abstract description 7
- 208000006673 asthma Diseases 0.000 claims abstract description 4
- 102100038595 Estrogen receptor Human genes 0.000 claims description 110
- 101710196141 Estrogen receptor Proteins 0.000 claims description 48
- 150000003839 salts Chemical class 0.000 claims description 14
- 102100029951 Estrogen receptor beta Human genes 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- 108010041356 Estrogen Receptor beta Proteins 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 230000003750 conditioning effect Effects 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 229950005953 camsilate Drugs 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000001055 chewing effect Effects 0.000 claims description 2
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 229940049920 malate Drugs 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 150000003016 phosphoric acids Chemical class 0.000 claims description 2
- 201000000498 stomach carcinoma Diseases 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 229950004288 tosilate Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 108010038795 estrogen receptors Proteins 0.000 abstract description 59
- 238000002474 experimental method Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 102000015694 estrogen receptors Human genes 0.000 abstract 2
- VMUXSMXIQBNMGZ-UHFFFAOYSA-N 3,4-dihydrocoumarin Chemical compound C1=CC=C2OC(=O)CCC2=C1 VMUXSMXIQBNMGZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 59
- 229940125904 compound 1 Drugs 0.000 description 20
- 230000001076 estrogenic effect Effects 0.000 description 18
- 229940125782 compound 2 Drugs 0.000 description 15
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 11
- 230000009182 swimming Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000019491 signal transduction Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 208000006402 Ductal Carcinoma Diseases 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 229940011871 estrogen Drugs 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 108020001756 ligand binding domains Proteins 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 201000010983 breast ductal carcinoma Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000004691 chief cell of stomach Anatomy 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- OVBICQMTCPFEBS-SATRDZAXSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound CC(O)=O.CC(O)=O.C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 OVBICQMTCPFEBS-SATRDZAXSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- FCLZCOCSZQNREK-UHFFFAOYSA-N Pyrrolidine, hydrochloride Chemical compound Cl.C1CCNC1 FCLZCOCSZQNREK-UHFFFAOYSA-N 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 108700032141 ganirelix Proteins 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101776289A CN101200460B (zh) | 2007-11-19 | 2007-11-19 | 二氢苯并吡喃酮类化合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101776289A CN101200460B (zh) | 2007-11-19 | 2007-11-19 | 二氢苯并吡喃酮类化合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101200460A CN101200460A (zh) | 2008-06-18 |
CN101200460B true CN101200460B (zh) | 2010-06-16 |
Family
ID=39515852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101776289A Active CN101200460B (zh) | 2007-11-19 | 2007-11-19 | 二氢苯并吡喃酮类化合物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101200460B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102108083B (zh) * | 2009-12-24 | 2013-05-22 | 中国科学院上海药物研究所 | 一类多环苯并吡喃酮类化合物及其制备方法和用途 |
CN102477043B (zh) * | 2010-11-30 | 2015-05-20 | 上海来益生物药物研究开发中心有限责任公司 | α-吡喃酮类化合物及其制备方法和应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1288892A (zh) * | 1999-09-16 | 2001-03-28 | 宋新荣 | 二氢杨梅素的制备方法及其用途 |
CN1337958A (zh) * | 1998-12-30 | 2002-02-27 | 信号药品公司 | 调节雌激素受体的化合物和方法 |
EP1426378A1 (de) * | 2002-12-02 | 2004-06-09 | MERCK PATENT GmbH | 2-Benzoylchromonderivate |
CN1890235A (zh) * | 2003-09-15 | 2007-01-03 | 西格诺药品有限公司 | 苯并吡喃酮化合物,其组合物以及用其进行治疗的方法 |
CN101066963A (zh) * | 2007-06-08 | 2007-11-07 | 浙江大学 | 多取代黄烷酮衍生物及制备和应用 |
JP2007291040A (ja) * | 2006-04-27 | 2007-11-08 | Hamamatsu Kagaku Gijutsu Kenkyu Shinkokai | 4位−カテコールエストロゲン生成阻害剤 |
-
2007
- 2007-11-19 CN CN2007101776289A patent/CN101200460B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1337958A (zh) * | 1998-12-30 | 2002-02-27 | 信号药品公司 | 调节雌激素受体的化合物和方法 |
CN1288892A (zh) * | 1999-09-16 | 2001-03-28 | 宋新荣 | 二氢杨梅素的制备方法及其用途 |
EP1426378A1 (de) * | 2002-12-02 | 2004-06-09 | MERCK PATENT GmbH | 2-Benzoylchromonderivate |
CN1890235A (zh) * | 2003-09-15 | 2007-01-03 | 西格诺药品有限公司 | 苯并吡喃酮化合物,其组合物以及用其进行治疗的方法 |
JP2007291040A (ja) * | 2006-04-27 | 2007-11-08 | Hamamatsu Kagaku Gijutsu Kenkyu Shinkokai | 4位−カテコールエストロゲン生成阻害剤 |
CN101066963A (zh) * | 2007-06-08 | 2007-11-07 | 浙江大学 | 多取代黄烷酮衍生物及制备和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101200460A (zh) | 2008-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11911397B2 (en) | Anordrin compositions and methods for treating diseases | |
Martineti et al. | ERβ is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components | |
CN103204838B (zh) | 多羟基苯并吡喃酮类化合物的合成及其抗肿瘤作用 | |
CN110267656B (zh) | 拉索昔芬调节膜结合雌激素信号的应用及治疗癌症的方法 | |
Cao et al. | Inhibition of the STAT3 signaling pathway contributes to the anti-melanoma activities of shikonin | |
Guo et al. | Inhibition of TMEM16A by natural product silibinin: potential lead compounds for treatment of lung adenocarcinoma | |
CN102283828B (zh) | 四羟基苯并吡喃酮类化合物的用途 | |
CN101200460B (zh) | 二氢苯并吡喃酮类化合物及其用途 | |
CN103732586A (zh) | 作为抗癌剂的乙酰基丹参酮iia(ata) | |
CN101185643B (zh) | (e)-1-(2,4-二羟基-5-(3-甲基-丁基-2-烯基)苯基)-3-(4-羟基苯基)丙烯-2-酮-1在药物中的应用 | |
CN101288666A (zh) | 异补骨脂查耳酮在制备抗肿瘤,骨质疏松,老年痴呆药中的应用 | |
CN101199509B (zh) | 2",2"-二甲基-2"h,4h-3,6"-二苯并吡喃-4-酮在制备抗肿瘤药物中的用途 | |
CN101249087A (zh) | 异补骨脂黄酮在制备抗肿瘤,骨质疏松,老年痴呆药中的应用 | |
Kim et al. | Torilis japonica extract fraction compound, EGFR-targeted inhibition of cancer abnormal metastasis in A549 lung cancer cells | |
CN101249088A (zh) | 补骨脂二氢黄酮甲醚在制备抗肿瘤,骨质疏松,老年痴呆药中的应用 | |
CN101139335B (zh) | 7-羟基-3-[(4-羟基)-3-((e)-3,7-二甲基-辛基-2,6-二烯基)苯基]-4h-1-苯并吡喃-4-酮的用途 | |
CN101129353B (zh) | 7-羟基-3-[(4-羟基)-3-(3-甲基-丁基-2-烯基)苯基]-4h-1-苯并吡喃-4-酮的用途 | |
CN102285948B (zh) | 四羟基苯并吡喃酮类化合物及其用途 | |
CN101249089A (zh) | 补骨脂二氢黄酮在制备抗肿瘤,骨质疏松,老年痴呆药中的应用 | |
CN101594874A (zh) | 6-烷氧基烷基雌二醇衍生物及使用方法 | |
Lin et al. | Luteolin inhibits ER-α expression through ILK inhibition is regulated by a pathway involving Twist and YB-1 | |
CN101474182A (zh) | G1在制备抗肿瘤、骨质疏松、老年痴呆药中的应用 | |
CN116687892A (zh) | 天然产物EuonyquinoneA的新用途 | |
CN102283823A (zh) | 四羟基丙烯酮类化合物的用途 | |
Stein | Defining the functional significance of estrogen-related receptor alpha in breast cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 102206 B101 room, innovation building, Zhongguancun Life Science Park, No. 29, life science Road, Beijing, Changping District Patentee after: BEIJING SHENOGEN BIOMEDICAL Co.,Ltd. Address before: 100085 A205 room two, A District, Zhongguancun biomedicine Park, 5 Haidian District Road, Beijing, China Patentee before: BEIJING SHENOGEN BIOMEDICAL Co.,Ltd. |
|
DD01 | Delivery of document by public notice |
Addressee: BEIJING SHENOGEN BIOMEDICAL Co.,Ltd. Document name: Notification of Passing Examination on Formalities |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20080618 Assignee: BEIJING SHENOGEN PHARMA Group Ltd. Assignor: BEIJING SHENOGEN BIOMEDICAL Co.,Ltd. Contract record no.: 2014990000184 Denomination of invention: Dihydrobenzopyrans ketone compound and uses thereof Granted publication date: 20100616 License type: Exclusive License Record date: 20140404 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20080618 Assignee: BEIJING SHENOGEN PHARMA Group Ltd. Assignor: BEIJING SHENOGEN BIOMEDICAL Co.,Ltd. Contract record no.: 2014990000184 Denomination of invention: Dihydrobenzopyrans ketone compound and uses thereof Granted publication date: 20100616 License type: Exclusive License Record date: 20140404 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Dihydrobenzopyrans ketone compound and uses thereof Effective date of registration: 20150413 Granted publication date: 20100616 Pledgee: Beijing Intellectual Property Management Co.,Ltd. Pledgor: BEIJING SHENOGEN BIOMEDICAL Co.,Ltd. Registration number: 2015990000274 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: BEIJING SHENOGEN PHARMA Group Ltd. Assignor: BEIJING SHENOGEN BIOMEDICAL Co.,Ltd. Contract record no.: 2014990000184 Date of cancellation: 20160310 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160511 Granted publication date: 20100616 Pledgee: Beijing Intellectual Property Management Co.,Ltd. Pledgor: BEIJING SHENOGEN BIOMEDICAL Co.,Ltd. Registration number: 2015990000274 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Dihydrobenzopyranone compounds and their uses Effective date of registration: 20220421 Granted publication date: 20100616 Pledgee: China Minsheng Bank Co.,Ltd. Beijing Branch Pledgor: BEIJING SHENOGEN BIOMEDICAL Co.,Ltd. Registration number: Y2022990000225 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230407 Granted publication date: 20100616 Pledgee: China Minsheng Bank Co.,Ltd. Beijing Branch Pledgor: Beijing shengnuoji Pharmaceutical Technology Co.,Ltd.|BEIJING SHENOGEN BIOMEDICAL Co.,Ltd. Registration number: Y2022990000225 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |